Open AccessLurasidone: Ten Years Treating Adults with Bipolar Depression
Author(s) -
Margarida Albuquerque,
João Facucho-Oliveira,
Daniel Esteves-Sousa,
Nuno Moura,
Daniel Neto,
P. Cintra
Publication year - 2021
Publication title -
revista portuguesa de psiquiatria e saúde mental/revista portuguesa de psiquiatria e saúde mental
Language(s) - English
Resource type - Journals
eISSN - 2184-5522
pISSN - 2184-5417
DOI - 10.51338/rppsm.2021.v7.i2.199
Subject(s) - lurasidone , bipolar disorder , schizophrenia (object oriented programming) , psychiatry , depression (economics) , paliperidone , medicine , antidepressant , aripiprazole , quetiapine , psychology , antipsychotic , mood , anxiety , economics , macroeconomics
Lurasidone is an atypical antipsychotic approved in 2010 in Canada and in the USA for the treatment of adults with schizophrenia or bipolar type I disorder. In 2014 it was approved in the European Union for the treatment of patients with 13 years‑old or older, with schizophrenia. Lurasidone is a benzisothiazole derivative with a binding profile that makes it an antidepressant candidate with a low metabolic impact. In patients with bipolar disorder, depressive episodes tend to be present for the majority of the time and are difficult to treat, as shown in multiple surveys indicating that more than three quarters of patients with bipolar depression receive at least two pharmaceutical drugs and more than one third receive three or more. Some relevant international guidelines include different first‑line options in the treatment of bipolar depression, among which is lurasidone. Considering the difficulties in treating depressive episodes in bipolar disorder, the EU marketing authorization limiting the use of lurasidone in schizophrenia only and the expectable commercialization in Portugal by 2021, we aim to review the literature regarding the efficacy and advantages of lurasidone for depressive episodes of bipolar disorder and to discuss the usefulness of approving this medication as an alternative treatment approach.